Barani Kumar Rajendran
Associate Research Scientist in PathologyDownloadHi-Res Photo
Cards
Appointments
Pathology
Primary
Contact Info
Yale School of Medicine
BML, Room 113
New Haven, CT 06510
United States
About
Titles
Associate Research Scientist in Pathology
Appointments
Pathology
Associate Research ScientistPrimary
Other Departments & Organizations
Research
Overview
Bioinformatics; Next Generation Sequencing (NGS), Single-cell Research; Precision medicine; Cancer Immunology, Computational Biology; Genomics; Computational Structural Biology, Spatial Transcriptomics.
ORCID
0000-0001-9675-7718- View Lab Website
Schalper Lab
Research at a Glance
Yale Co-Authors
Frequent collaborators of Barani Kumar Rajendran's published research.
Publications Timeline
A big-picture view of Barani Kumar Rajendran's research output by year.
Dianqing (Dan) Wu, PhD
Hongyue Zhou
Julie Goodwin, MD
Kishu Ranjan, PhD
Kurt Schalper, MD, PhD
Wenwen Tang, PhD
29Publications
710Citations
Publications
2025
Editorial: Unveiling inflammaging – mechanistic insights on aging and related diseases
Satyanarayanan S, Rajendran B. Editorial: Unveiling inflammaging – mechanistic insights on aging and related diseases. Frontiers In Medicine 2025, 12: 1607050. PMID: 40330777, PMCID: PMC12052547, DOI: 10.3389/fmed.2025.1607050.Peer-Reviewed Original ResearchAltmetricThe molecular determinants regulating redox signaling in diabetic endothelial cells
Srivastava S, Kopasz-Gemmen O, Thurman A, Rajendran B, Selvam M, Kumar S, Srivastava R, Suresh M, Kumari R, Goodwin J, Inoki K. The molecular determinants regulating redox signaling in diabetic endothelial cells. Frontiers In Pharmacology 2025, 16: 1563047. PMID: 40290438, PMCID: PMC12023289, DOI: 10.3389/fphar.2025.1563047.Peer-Reviewed Original ResearchCitationsAltmetricConceptsReactive oxygen speciesProcess of oxidative phosphorylationAberrant activation of mTOR signalingNutrient-sensing kinaseCellular signaling pathwaysCellular ROS levelsLoss of AMPKOxygen speciesActivation of mTOR signalingReactive oxygen species productionIncreased ROSTranscription of pro-inflammatory cytokinesActivation of MAPKCell powerhouseGenerate ATPCell oxidative statusRenal endothelial cellsOxidative phosphorylationRedox signalingDamaged DNASignaling pathwayMolecular determinantsMTOR signalingPI3KAberrant activationIL-4 mediated TAP2 downregulation is a dominant and reversible mechanism of immune evasion and immunotherapy resistance in non-small cell lung cancer
Ranjan K, Rajendran B, Deen I, Costantini A, de Rodas M, Desai S, Scallo F, Gianino N, Ferrone S, Schalper K. IL-4 mediated TAP2 downregulation is a dominant and reversible mechanism of immune evasion and immunotherapy resistance in non-small cell lung cancer. Molecular Cancer 2025, 24: 80. PMID: 40091029, PMCID: PMC11912681, DOI: 10.1186/s12943-025-02276-z.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsMeSH KeywordsATP Binding Cassette Transporter, Subfamily B, Member 2ATP Binding Cassette Transporter, Subfamily B, Member 3Carcinoma, Non-Small-Cell LungCD8-Positive T-LymphocytesCell Line, TumorDown-RegulationDrug Resistance, NeoplasmGene Expression Regulation, NeoplasticHumansImmune EvasionImmunotherapyInterleukin-4Lung NeoplasmsLymphocytes, Tumor-InfiltratingConceptsNon-small cell lung cancerHuman non-small cell lung cancerTumor-infiltrating lymphocytesImmune checkpoint blockersAntigen presentation machineryT cell killingCell lung cancerNon-small cell lung cancer cellsIL-4Lung cancerIL-4 transcriptionCheckpoint blockersImmunotherapy resistancePD-1Sensitive to immune checkpoint blockersImmune evasionAutologous tumor-infiltrating lymphocytesEffector tumour-infiltrating lymphocytesAggressive non-small cell lung cancerTAP2 expressionMechanisms of immune evasionIntratumoral myeloid cellsPD-1 blockadeAnti-cancer immunityAutologous co-cultures
2024
Renal Angptl4 is a key fibrogenic molecule in progressive diabetic kidney disease
Srivastava S, Zhou H, Shenoi R, Morris M, Lainez-Mas B, Goedeke L, Rajendran B, Setia O, Aryal B, Kanasaki K, Koya D, Inoki K, Dardik A, Bell T, Fernández-Hernando C, Shulman G, Goodwin J. Renal Angptl4 is a key fibrogenic molecule in progressive diabetic kidney disease. Science Advances 2024, 10: eadn6068. PMID: 39630889, PMCID: PMC11616692, DOI: 10.1126/sciadv.adn6068.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsAngiopoietin-like 4Diabetic kidney diseaseIntegrin B1Fibrogenic moleculesMutant miceSTING pathway activationIncreased fatty acid oxidationProgressive diabetic kidney diseaseDiabetic kidneyKidney diseaseReduced epithelial-to-mesenchymal transitionEpithelial-to-mesenchymal transitionFatty acid oxidationExpression of pro-inflammatory cytokinesTargeted pharmacological therapiesGene expressionMitochondrial damageEndothelial-to-mesenchymal transitionPro-inflammatory cytokinesPathway activationPharmacological therapyControl miceIntegrinAcid oxidationFibrogenic phenotypeAdvances in predicting breast cancer driver mutations: Tools for precision oncology (Review)
Hao W, Rajendran B, Cui T, Sun J, Zhao Y, Palaniyandi T, Selvam M. Advances in predicting breast cancer driver mutations: Tools for precision oncology (Review). International Journal Of Molecular Medicine 2024, 55: 6. PMID: 39450552, PMCID: PMC11537269, DOI: 10.3892/ijmm.2024.5447.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsDisease-free survivalBreast cancerPrecision medicine approachAvailability of high-throughput sequencingPrecision oncologyTherapeutic optionsDriver mutationsDisease-free survival of patientsCancer driver gene identificationDriver gene identificationMedicine approachHigh-throughput sequencingSurvival of patientsTargeted therapeutic optionsFraction of patientsCancer driver mutationsTargeted therapeutic approachesBreast cancer treatmentIdentification of driver mutationsBreast cancer mutationsModern era of medicineCancer-specific biomarkersGene identificationCancer DatabaseCancer mutationsWnt5 controls splenic myelopoiesis and neutrophil functional ambivalency during DSS-induced colitis
Luan Y, Hu J, Wang Q, Wang X, Li W, Qu R, Yang C, Rajendran B, Zhou H, Liu P, Zhang N, Shi Y, Liu Y, Tang W, Lu J, Wu D. Wnt5 controls splenic myelopoiesis and neutrophil functional ambivalency during DSS-induced colitis. Cell Reports 2024, 43: 113934. PMID: 38461416, PMCID: PMC11064424, DOI: 10.1016/j.celrep.2024.113934.Peer-Reviewed Original ResearchCitationsAltmetricConceptsCD8<sup>+</sup> T cell activationNeutrophil productionNeutrophil plasticitySplenic extramedullary myelopoiesisFamily member 5T cell activationInnate immune cellsSplenic stromal cellsDSS-induced colitisAnti-inflammatory protectionCD101 expressionPro-inflammatory activitySplenic myelopoiesisExtramedullary myelopoiesisBone marrowImmune cellsSplenic neutrophilsMember 5Autoimmune diseasesInflammatory outcomesCell activationStromal cellsColitisSplenic productionElevated numbersThe CUL5 E3 ligase complex negatively regulates central signaling pathways in CD8+ T cells
Liao X, Li W, Zhou H, Rajendran B, Li A, Ren J, Luan Y, Calderwood D, Turk B, Tang W, Liu Y, Wu D. The CUL5 E3 ligase complex negatively regulates central signaling pathways in CD8+ T cells. Nature Communications 2024, 15: 603. PMID: 38242867, PMCID: PMC10798966, DOI: 10.1038/s41467-024-44885-0.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsCD8+ T cellsT cellsCancer immunotherapyMouse CD8+ T cellsAnti-tumor immunityTumor growth inhibition abilityAnti-tumor effectsInhibition of neddylationCD8Effector functionsTCR stimulationIL2 signalingCentral signaling pathwaysCore signaling pathwaysEffector activityNegative regulatory mechanismsTranslational implicationsImmunotherapyGrowth inhibition abilityCytokine signalingTCRProteomic alterationsSignaling pathwayCancerCRISPR-based screens
2023
606 IMpower110: Tertiary lymphoid structures (TLS) and clinical outcomes in advanced non-small cell lung cancer (NSCLC) treated with first-line atezolizumab or chemotherapy
Srivastava M, Gayevskiy V, Ma V, Estay I, Rodas M, Rajendran B, Hoang T, Ballinger M, Amin R, Herbst R, Marinis F, Giaccone G, Jassem J, Spigel D, Schalper K, Koeppen H, Shames D, Johnston R, Giltnane J, Nabet B. 606 IMpower110: Tertiary lymphoid structures (TLS) and clinical outcomes in advanced non-small cell lung cancer (NSCLC) treated with first-line atezolizumab or chemotherapy. 2023, a690-a690. DOI: 10.1136/jitc-2023-sitc2023.0606.Peer-Reviewed Original ResearchCitationsBiomarkers and biosensors for early cancer diagnosis, monitoring and prognosis
Wahab M, Palaniyandi T, Ravi M, viswanathan S, Baskar G, Surendran H, Gangadharan S, Rajendran B. Biomarkers and biosensors for early cancer diagnosis, monitoring and prognosis. Pathology - Research And Practice 2023, 250: 154812. PMID: 37741139, DOI: 10.1016/j.prp.2023.154812.Peer-Reviewed Original ResearchCitationsConceptsEarly cancer diagnosisBiosensorEarly cancer detectionCancer biomarkersChip modelSuch biomarkersEngineering technologyBiological samplesCancer typesRecent advancementsEarly detectionNucleic acidsEarly diagnostic markerCancer detectionDevelopment of technologyGlobal socioeconomic impactTumor cell DNAProstate cancerMajor challengeBiomedical engineering technologyTherapeutic outcomesDetectionDiagnostic markerTechnologyParticular cancer typesPharmacological effect of gold nanoparticles from red algae Halymenia venusta on A549 cell line
Baskar G, Palaniyandi T, Viswanathan S, Wahab M, Surendran H, Ravi M, Rajendran B, Govindasamy G, Sivaji A, Kaliamoorthy S. Pharmacological effect of gold nanoparticles from red algae Halymenia venusta on A549 cell line. Inorganic Chemistry Communications 2023, 155: 111005. DOI: 10.1016/j.inoche.2023.111005.Peer-Reviewed Original ResearchCitationsConceptsUltra-violet spectroscopyGold nanoparticlesSurface plasmon resonanceFourier transform infra-red spectroscopy (FTIR) analysesX-ray diffraction spectroscopyStable gold nanoparticlesInfra-red spectroscopy analysisGreen synthesisDiffraction spectroscopyFree radical scavenging capabilityRadical scavenging capabilitySpectroscopy analysisAnalytical techniquesCrystalline structurePlasmon resonanceNanoparticlesA549 cell lineReactive oxygen species assaysPromising anti-cancer potentialAntiproliferative activityElectron microscopyAntimicrobial activitySpectroscopyScavenging capabilityAnti-cancer potential
Academic Achievements & Community Involvement
Activities
activity Frontiers in Medicine
2022 - PresentJournal ServiceGuest Editoractivity Pharmacognosy Magazine
2022 - PresentJournal ServiceEditorial Board Memberactivity Frontiers in Bioinformatics
2022 - PresentJournal ServiceGuest Editoractivity Scientific Reports
2024 - PresentJournal ServiceRevieweractivity Frontiers in Oncology
2022 - PresentJournal ServiceReviewer
Links
Get In Touch
Contacts
Mailing Address
Yale School of Medicine
BML, Room 113
New Haven, CT 06510
United States